Iqvia CEO Ari Bousbib sells $26.1m in company stock By Investing.com

Ari Bousbib, Chairman, Chief Executive Officer, and President of IQVIA Holdings Inc. (), sold common stock totaling approximately $26.09 million on July 29, 2026. The transactions involved the sale of 106,279 shares at prices ranging from $244.60 to $247.18 per share.

These sales followed Mr. Bousbib’s acquisition of 156,206 shares of common stock through the exercise of stock appreciation rights on the same date. These rights, which were set to expire on February 2, 2027, were exercised at a price of $78.21 per share, representing a total value of approximately $12.22 million. The timing of these transactions comes as IQVIA stock trades near its 52-week high of $251.36, having delivered a strong 28% return over the past year.

Additionally, Mr. Bousbib disposed of 49,927 shares of common stock, valued at approximately $12.22 million, with prices ranging from $244.60 to $247.00 per share.

Following these transactions, Mr. Bousbib directly holds 835,941 shares of IQVIA common stock. An additional 543,302 shares are held indirectly through the Orohena Trust. According to InvestingPro analysis, IQVIA appears undervalued at current levels, with the stock showing a “GOOD” financial health score. Investors seeking deeper insights can access the comprehensive Pro Research Report, available for IQVIA and 1,400+ other US equities.

In other recent news, IQVIA Holdings reported that its second-quarter adjusted earnings and revenue exceeded Wall Street expectations. The company achieved adjusted diluted earnings per share of $3.15, surpassing the analyst forecast of $3.04, while revenue reached $4.37 billion, beating the expected $4.30 billion. This performance was attributed to stronger organic growth, better-than-expected operating performance, and increased demand in clinical and commercial sectors. Following these results, Truist Securities raised its price target for IQVIA to $300 from $245, maintaining a Buy rating, and highlighted the company’s AI strategy and positive demand environment. Similarly, Stifel increased its price target to $276 from $220, also maintaining a Buy rating, citing improving markets and IQVIA’s strengthening position within them. Both firms expect further positive trends in estimates and valuations. These developments reflect a growing confidence in IQVIA’s future prospects among analysts.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.